Cystic fibrosis (CF), a genetic disorder impacting around 100,000 individuals worldwide, arises from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Over recent decades, researchers have developed various small-molecule therapies that alleviate the severity of the disease. Despite these advancements, significant treatment hurdles remain. A recent study has unveiled a promising gene therapy that successfully addresses an “untreatable” mutation linked to a severe form of cystic fibrosis. The findings are detailed in a publication in Science Translational Medicine titled “Functional correction of the untreatable CFTR 1717-IG>A mutation through mRNA- and sgRNA-optimized base editing.”
Current Treatment Landscape
While existing therapies have shown efficacy in treating patients with the most prevalent CF mutation, F508del, they often fall short for those with alternative mutations. One such mutation, 1717-1G>A, is relatively common among CF patients but lacks approved therapies due to its classification as a splicing mutation, leading to negligible protein production. Alarmingly, around 10% of individuals with cystic fibrosis are ineligible for available CFTR modulator therapies, particularly those with severe splicing mutations that cause frameshifts and the creation of premature termination codons.
Targeting the Untreatable Mutation
The focus of the new therapy is the 1717-1G>A mutation, as outlined in the paper authored by scientists from the University of Trento and their collaborators. They developed an innovative adenine base editing approach aimed at correcting this specific mutation. The team utilized the SpRY-ABE9 system, delivering optimized RNAs for the base editor and single guide RNA (sgRNA) to achieve functional correction in models derived from patients.
Advantages of Base Editing
The researchers chose base editing over traditional editing techniques due to its typically higher nucleotide modification efficiencies and its streamlined approach, which requires only the editor and an sgRNA. This method has previously shown promise in other cystic fibrosis studies, reinforcing the validity of their approach.
Early Successes in Editing Efficiency
Employing their ABE9 base editor and a modified CRISPR-Cas9 tool, the scientists successfully edited up to 30% of target DNA in human embryonic kidney cell lines and patient-derived airway epithelial cells, all while maintaining minimal off-target effects. Importantly, they demonstrated the correction of the mutation in intestinal organoids sourced from CF patients, as evidenced by restored CFTR activity.
Promising Future Research
While the current results are encouraging, further research—especially involving animal models—is essential to comprehensively evaluate the therapy’s effectiveness. The initial findings indicate an editing efficiency of 13%, and prior research suggests that even a 10% efficiency could be sufficient for achieving functional recovery. This bodes well for patients whose cystic fibrosis is attributed to the 1717-1G>A mutation.
Conclusion
The recent advancements in CRISPR base editing represent a significant leap forward in the quest to treat cystic fibrosis more effectively. With ongoing research and potential future trials, there is hope for improved therapies that could transform the lives of those affected by this challenging genetic disorder.
- Key Takeaways:
- Cystic fibrosis affects around 100,000 people globally due to CFTR mutations.
- A promising new gene therapy targets the 1717-1G>A mutation, previously deemed untreatable.
- The adenine base editing strategy shows potential with a 30% editing efficiency and minimal off-target effects.
- Further studies are needed to confirm efficacy, particularly in animal models.
- This research could significantly benefit patients who currently lack effective treatment options.
Read more → www.genengnews.com